From Lab to Patient: How Tetraneuron's Gene Therapy Approach is Tackling Alzheimer's Disease

"When you are seeing great results in your research lab, you think that everything has been done. But then when you try to humanise your drug, a new adventure starts, because the CMC process is very difficult. In my opinion, it's as difficult as demonstrating efficacy." - Mari Carmen Álvarez

Mari Carmen Álvarez PhD. is the Managing Director of Tetraneuron, a pioneering Spanish biotech developing novel gene therapies for neurodegenerative diseases. With nearly two decades in biotech leadership, she founded Valencia University's first biotech spin-off and brings expertise spanning innovation management, business development, and fundraising from seed to Series A.

In the latest PharmaSource podcast episode, Mari Carmen explains why scaling gene therapy development requires more than strong science, how to navigate the complex CDMO ecosystem, and what she learned from a previous biotech failure that shaped her approach to leadership and patient impact.

Full interview: https://pharmasource.global/content/podcast/from-lab-to-patient-how-tetraneurons-gene-therapy-approach-is-tackling-alzheimers-disease/